RU2004126862A - Соли валсартана - Google Patents
Соли валсартана Download PDFInfo
- Publication number
- RU2004126862A RU2004126862A RU2004126862/04A RU2004126862A RU2004126862A RU 2004126862 A RU2004126862 A RU 2004126862A RU 2004126862/04 A RU2004126862/04 A RU 2004126862/04A RU 2004126862 A RU2004126862 A RU 2004126862A RU 2004126862 A RU2004126862 A RU 2004126862A
- Authority
- RU
- Russia
- Prior art keywords
- salt
- valsartan
- pharmaceutically acceptable
- guinier
- powder
- Prior art date
Links
- 239000004072 C09CA03 - Valsartan Substances 0.000 title claims 16
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical class C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 title claims 16
- 229960004699 valsartan Drugs 0.000 title claims 16
- 150000003839 salts Chemical class 0.000 claims 16
- 230000008018 melting Effects 0.000 claims 10
- 238000002844 melting Methods 0.000 claims 10
- 238000004279 X-ray Guinier Methods 0.000 claims 7
- 238000000634 powder X-ray diffraction Methods 0.000 claims 6
- 159000000007 calcium salts Chemical class 0.000 claims 4
- ODYFGDACHPDINU-UHFFFAOYSA-N O.O.O.[Ca] Chemical compound O.O.O.[Ca] ODYFGDACHPDINU-UHFFFAOYSA-N 0.000 claims 3
- 230000009477 glass transition Effects 0.000 claims 3
- 159000000003 magnesium salts Chemical class 0.000 claims 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 3
- 102000003729 Neprilysin Human genes 0.000 claims 2
- 108090000028 Neprilysin Proteins 0.000 claims 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 2
- 150000004682 monohydrates Chemical class 0.000 claims 2
- 230000007704 transition Effects 0.000 claims 2
- 150000004684 trihydrates Chemical class 0.000 claims 2
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 claims 1
- 239000005541 ACE inhibitor Substances 0.000 claims 1
- 229940123338 Aldosterone synthase inhibitor Drugs 0.000 claims 1
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 claims 1
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 claims 1
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 claims 1
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 claims 1
- 229940123934 Reductase inhibitor Drugs 0.000 claims 1
- 238000010521 absorption reaction Methods 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 239000002170 aldosterone antagonist Substances 0.000 claims 1
- 229940083712 aldosterone antagonist Drugs 0.000 claims 1
- 239000000480 calcium channel blocker Substances 0.000 claims 1
- ZQNPDAVSHFGLIQ-UHFFFAOYSA-N calcium;hydrate Chemical compound O.[Ca] ZQNPDAVSHFGLIQ-UHFFFAOYSA-N 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- -1 dicalcium salt pentahydrate Chemical compound 0.000 claims 1
- 239000002934 diuretic Substances 0.000 claims 1
- 230000001882 diuretic effect Effects 0.000 claims 1
- 230000009977 dual effect Effects 0.000 claims 1
- 239000002308 endothelin receptor antagonist Substances 0.000 claims 1
- 238000002329 infrared spectrum Methods 0.000 claims 1
- ZATZOOLBPDMARD-UHFFFAOYSA-N magnesium;hydrate Chemical compound O.[Mg] ZATZOOLBPDMARD-UHFFFAOYSA-N 0.000 claims 1
- YYINWHOQKIUBNL-UHFFFAOYSA-N magnesium;trihydrate Chemical compound O.O.O.[Mg] YYINWHOQKIUBNL-UHFFFAOYSA-N 0.000 claims 1
- 150000004686 pentahydrates Chemical class 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 239000002461 renin inhibitor Substances 0.000 claims 1
- 229940086526 renin-inhibitors Drugs 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 150000004685 tetrahydrates Chemical class 0.000 claims 1
- 150000004104 valsartan derivatives Chemical class 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35419902P | 2002-02-04 | 2002-02-04 | |
| US60/354,199 | 2002-02-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2004126862A true RU2004126862A (ru) | 2005-06-27 |
Family
ID=27734333
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2004126862/04A RU2004126862A (ru) | 2002-02-04 | 2003-02-03 | Соли валсартана |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US6869970B2 (enExample) |
| EP (1) | EP1474402A1 (enExample) |
| JP (2) | JP4895475B2 (enExample) |
| KR (3) | KR20120054667A (enExample) |
| CN (2) | CN100548993C (enExample) |
| AU (1) | AU2003214054B2 (enExample) |
| BR (1) | BR0307442A (enExample) |
| CA (2) | CA2776902A1 (enExample) |
| CO (1) | CO5611107A2 (enExample) |
| EC (1) | ECSP045221A (enExample) |
| MX (1) | MXPA04007525A (enExample) |
| NO (1) | NO328155B1 (enExample) |
| NZ (1) | NZ534560A (enExample) |
| PL (1) | PL370481A1 (enExample) |
| RU (1) | RU2004126862A (enExample) |
| WO (1) | WO2003066606A1 (enExample) |
| ZA (1) | ZA200405698B (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7468390B2 (en) | 2002-01-17 | 2008-12-23 | Novartis Ag | Methods of treatment and pharmaceutical composition |
| US6869970B2 (en) | 2002-02-04 | 2005-03-22 | Novartis Ag | Crystalline salt forms of valsartan |
| ATE409476T1 (de) * | 2002-06-13 | 2008-10-15 | Novartis Pharma Gmbh | Calciumsalze von statinen aus indol |
| US20040242661A1 (en) * | 2003-03-17 | 2004-12-02 | Igor Rukhman | Polymorphs of valsartan |
| AU2004238546A1 (en) * | 2003-05-16 | 2004-11-25 | Novartis Ag | Pharmaceutical composition comprising valsartan |
| CN1882334A (zh) * | 2003-11-14 | 2006-12-20 | 诺瓦提斯公司 | 用于治疗肾病综合征的at1－受体拮抗剂 |
| ITMI20032267A1 (it) * | 2003-11-21 | 2005-05-22 | Dinamite Dipharma S P A In Forma A Bbreviata Diph | Procdimento per la preparzione di valsartan e suoi intermedi |
| WO2005049587A1 (en) * | 2003-11-21 | 2005-06-02 | Ranbaxy Laboratories Limited | Process for preparation of biphenyl tetrazole |
| TWI328006B (en) * | 2003-12-26 | 2010-08-01 | Nissan Chemical Ind Ltd | Crystal form of quinoline compound and process for its production |
| DE502004002443D1 (de) * | 2004-04-15 | 2007-02-08 | Helm Ag | Verfahren zur Herstellung von freifliessenden, pulverförmigen Valsartan-Adsorbaten |
| AR050043A1 (es) * | 2004-08-03 | 2006-09-20 | Novartis Ag | Metodos para mejorar la biodisponibilidad y composicion farmaceutica para trastornos cardiovasculares |
| WO2006021443A2 (en) * | 2004-08-26 | 2006-03-02 | Novartis Ag | Composition comprising an at1 receptor blocker and a macrolide t-cell immunomodulator |
| KR20070074576A (ko) | 2004-10-29 | 2007-07-12 | 코와 가부시키가이샤 | 사구체 질환 치료제 |
| US20100028439A1 (en) * | 2005-05-23 | 2010-02-04 | Elan Pharma International Limited | Nanoparticulate stabilized anti-hypertensive compositions |
| AR057882A1 (es) | 2005-11-09 | 2007-12-26 | Novartis Ag | Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra |
| WO2008035364A2 (en) * | 2006-06-23 | 2008-03-27 | Usv Limited | Process for the preparation of micronized valsartan |
| PE20080991A1 (es) | 2006-06-27 | 2008-09-05 | Novartis Ag | Formas de dosificacion solidas de valsartan, amlodipina e hidroclorotiazida y metodo para elaborarlas |
| WO2008018843A1 (en) * | 2006-08-08 | 2008-02-14 | Ulkar Kimya Sanayi Ve Ticaret As | Process for producing useful salts form of biphenyl-tetrazole compounds |
| PE20080907A1 (es) * | 2006-08-31 | 2008-08-22 | Novartis Ag | Sistema de suministro de farmaco oral gastro-retentivo de liberacion extendida para valsartan |
| US8071596B2 (en) | 2007-01-12 | 2011-12-06 | Concert Pharmaceuticals, Inc. | Endothelin receptor antagonists |
| US8080549B2 (en) * | 2007-01-12 | 2011-12-20 | Concert Pharmaceuticals, Inc. | Endothelin receptor antagonists |
| CN101396366B (zh) * | 2007-09-25 | 2010-10-13 | 浙江华海药业股份有限公司 | 含缬沙坦的固体口服制剂及其制备方法 |
| ES2336755B1 (es) * | 2008-10-07 | 2011-01-21 | Activery Biotech, S.L. | Procedimiento para la preparacion de combinaciones de valsartan y simvastatina. |
| JP2011063518A (ja) * | 2009-09-15 | 2011-03-31 | Tohoku Univ | Ａｒｂ及び／又はグリタゾン系血糖降下物質を含有するｏａｔｐ−ｒ遺伝子発現増強組成物 |
| AR082435A1 (es) | 2010-08-03 | 2012-12-05 | Novartis Ag | Valsartan altamente cristalino |
| CN103012301B (zh) * | 2013-01-05 | 2015-06-17 | 江苏施美康药业股份有限公司 | 缬沙坦甲酯碱金属盐及其制备方法 |
| DE102014004512A1 (de) * | 2014-03-28 | 2015-10-01 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Bereich Universitätsmedizin | Anorganisch-organische Hybridverbindung |
| WO2017012600A1 (en) | 2015-07-20 | 2017-01-26 | Zentiva, K.S. | A pharmaceutical composition containing valsartan and sacubitril and methods for preparation and stabilization thereof |
| WO2018002673A1 (en) | 2016-07-01 | 2018-01-04 | N4 Pharma Uk Limited | Novel formulations of angiotensin ii receptor antagonists |
| EP3498698A1 (en) | 2017-12-15 | 2019-06-19 | Mankind Pharma Ltd | Solid forms of valsartan disodium and process of preparation thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL97219A (en) * | 1990-02-19 | 1995-12-08 | Ciba Geigy Ag | Biphenyl substituted aliphatic amino compounds process for their preparation and pharmaceutical compositions containing them |
| MX9707683A (es) * | 1995-04-07 | 1997-12-31 | Novartis Ag | Composiciones de combinacion que contienen benazepril o benazeprilat y valsartan. |
| ES2099031B1 (es) | 1995-05-31 | 1997-12-01 | Esteve Labor Dr | Nuevos polimorfos de diclorhidrato de lesopitron y sus formas hidratadas, procedimientos de preparacion y composiciones que los contienen. |
| US5877193A (en) * | 1996-07-19 | 1999-03-02 | Hoffmann-La Roche Inc. | Use of N-(4-aryl-thiazol-2-yl)-sulfonamides |
| EE9900377A (et) * | 1997-02-28 | 2000-04-17 | Burstein Laboratories, Inc. | Labor laserkettas |
| US6641886B1 (en) * | 1999-03-23 | 2003-11-04 | Flexplay Technologies, Inc. | Directory read inhibitor for optical storage media |
| JP2001155346A (ja) * | 1999-11-26 | 2001-06-08 | Toshiba Corp | 情報記録媒体、情報記録装置、情報記録方法、情報再生装置、情報再生方法 |
| SK16372002A3 (sk) | 2000-04-24 | 2003-04-01 | Teva Pharmaceutical Industries Ltd. | Zolpidem hemitartrát |
| US20020132839A1 (en) * | 2000-06-22 | 2002-09-19 | Ganter Sabina Maria | Tablet formulations comprising valsartan |
| US20030207930A1 (en) | 2000-07-19 | 2003-11-06 | Erwin Marti | Valsartan salts |
| US6869970B2 (en) | 2002-02-04 | 2005-03-22 | Novartis Ag | Crystalline salt forms of valsartan |
-
2003
- 2003-01-29 US US10/353,389 patent/US6869970B2/en not_active Expired - Lifetime
- 2003-02-03 JP JP2003565980A patent/JP4895475B2/ja not_active Expired - Fee Related
- 2003-02-03 CA CA2776902A patent/CA2776902A1/en not_active Abandoned
- 2003-02-03 CN CNB038032600A patent/CN100548993C/zh not_active Expired - Lifetime
- 2003-02-03 CA CA2474424A patent/CA2474424C/en not_active Expired - Fee Related
- 2003-02-03 NZ NZ534560A patent/NZ534560A/en not_active IP Right Cessation
- 2003-02-03 BR BR0307442-0A patent/BR0307442A/pt active Search and Examination
- 2003-02-03 EP EP03709700A patent/EP1474402A1/en not_active Withdrawn
- 2003-02-03 AU AU2003214054A patent/AU2003214054B2/en not_active Ceased
- 2003-02-03 PL PL03370481A patent/PL370481A1/xx not_active Application Discontinuation
- 2003-02-03 WO PCT/EP2003/001047 patent/WO2003066606A1/en not_active Ceased
- 2003-02-03 CN CN200910167071XA patent/CN101633646B/zh not_active Expired - Lifetime
- 2003-02-03 MX MXPA04007525A patent/MXPA04007525A/es active IP Right Grant
- 2003-02-03 RU RU2004126862/04A patent/RU2004126862A/ru unknown
- 2003-02-03 KR KR1020127011954A patent/KR20120054667A/ko not_active Ceased
- 2003-02-03 KR KR10-2004-7012006A patent/KR20040081178A/ko not_active Ceased
- 2003-02-03 KR KR1020117020401A patent/KR20110101257A/ko not_active Ceased
-
2004
- 2004-07-16 ZA ZA200405698A patent/ZA200405698B/en unknown
- 2004-08-04 EC EC2004005221A patent/ECSP045221A/es unknown
- 2004-09-01 NO NO20043660A patent/NO328155B1/no not_active IP Right Cessation
- 2004-09-02 CO CO04086386A patent/CO5611107A2/es not_active Application Discontinuation
- 2004-12-15 US US11/013,111 patent/US8058301B2/en active Active
-
2009
- 2009-06-10 JP JP2009139245A patent/JP5303370B2/ja not_active Expired - Fee Related
-
2011
- 2011-09-28 US US13/247,281 patent/US8329919B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2004126862A (ru) | Соли валсартана | |
| JP2009235086A5 (enExample) | ||
| JP2005517696A5 (enExample) | ||
| RU2009136593A (ru) | Кристаллические формы 6-[2-(метилкарбамоил)фенилсульфанил]-3-е-[2-(пиридин-2-ил)этенил]индазола, пригодные для лечения аномального роста клеток у илекопитаюших | |
| RU2011127679A (ru) | Высокоактивные молекулярные сита со структурой типа мтт | |
| JP2009517023A5 (enExample) | ||
| NO326504B1 (no) | Valsartansalter, fremgangsmate for fremstilling derav, anvendelse derav samt farmasoytisk preparat inneholdende en slik forbindelse | |
| Okada et al. | Effects of grinding and firing conditions on CaAl2Si2O8 phase formation by solid-state reaction of kaolinite with CaCO3 | |
| ZA200807025B (en) | Beta-crystalline form of perindopril arginine salt, method for making same, and pharmaceutical compositions containing same | |
| CA2252982A1 (en) | Substituted indazole derivatives and their use as inhibitors phosphodiesterase (pde) type iv and the production of tumor necrosis factor (tnf) | |
| RU2004106528A (ru) | Кристаллические формы | |
| Khandavilli et al. | High solubility crystalline hydrates of Na and K furosemide salts | |
| AU2001264804A1 (en) | 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl- [2,3']bipyridinyl in pure crystalline form and process for synthesis | |
| WO2001092230A1 (en) | 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl- [2,3']bipyridinyl in pure crystalline form and process for synthesis | |
| ME02456B (me) | Kristalni oblik argininske soli perindoprila, postupak njene proizvodnje i farmaceutske smeše koje je sadrže | |
| KR20190041473A (ko) | 5r-벤질옥시아미노 피페리딘-2s-포메이트 옥살레이트의 개선된 제조방법 | |
| HK1052170A1 (zh) | 新型化合物抑制因子xa活度 | |
| Di Martino et al. | A new tetrahydrated form of sodium naproxen | |
| AU2001292907B2 (en) | 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl in pure crystalline form and process for synthesis | |
| SK287644B6 (sk) | Kryštalický N-(trans)-4-izopropylcyklohexylkarbonyl)-D- fenylalanín vo forme C a spôsob jeho prípravy | |
| PL199714B1 (pl) | Nowy sposób syntezy estrów N-[(S)-1-karboksybutylo]-(S)-alaniny | |
| PT922048E (pt) | Processo para a preparacao de n-¬(1-"butil-4-piperidinil)metil|-3,4-di-hidro-2h-¬1,3|oxazino¬3,2-a|indolo-10-carboxamida seus sais e compostos intermedios do processo | |
| US20080188517A1 (en) | Crystalline forms of a factor xa inhibitor | |
| RU2009121646A (ru) | Соль алискирена и оротовой кислоты | |
| KR100878140B1 (ko) | 아토바스타틴의 스트론튬염 또는 이의 수화물, 및 이를포함하는 약학 조성물 |